ViewRay Story

<div class='circular--portrait' style='background:#347AFC;color: #ffffff;font-size:3em;'>VRA</div>
VRAY -- USA Stock  

USD 5.29  0.16  3.12%

The upcoming quarterly report is expected on the 11th of March 2021. The stock experiences an active upward rally. ViewRay Issuance Purchase of Equity Shares is fairly stable at the moment as compared to the past year. ViewRay reported Issuance Purchase of Equity Shares of 24.07 Million in 2020. Share Based Compensation is likely to rise to about 1 M in 2021, whereas Net Income Per Employee is likely to drop (377.7 K) in 2021. As many of us are excited about healthcare space, it is fair to break down ViewRay as a unique alternative.
Published over two weeks ago
View all stories for ViewRay | View All Stories
How much will ViewRay owe in February?
The company currently holds 66.76 M in liabilities with Debt to Equity (D/E) ratio of 0.44, which is about average as compared to similar companies. ViewRay has a current ratio of 3.07, suggesting that it is liquid enough and is able to pay its financial obligations when due.
ViewRay financial leverage ratio helps determine the effect of debt on the overall profitability of the company. It measures the total debt position of ViewRay, including all of ViewRay's outstanding debt obligations, and compares it with the equity. In simple terms, the high financial leverage means the cost of production, together with running the business day-to-day, is high, whereas, lower financial leverage implies lower fixed cost investment in the business and generally considered by investors to be a good sign. So if creditors own a majority of ViewRay assets, the company is considered highly leveraged. Understanding the composition and structure of overall ViewRay debt and outstanding corporate bonds gives a good idea of how risky the capital structure of a business is and if it is worth investing in it. Please read more on our technical analysis page.

Understanding ViewRay Total Debt

ViewRay liabilities are broken down into two parts on the balance sheet. These are short-term (or current) obligations and long-term debt. ViewRay has to fulfill its short-term liabilities in this reporting year and should be no more than 12 months old. Long-term debt, on the other hand, is anything beyond the 12-month payment timeframe. Common short-term liabilities found on ViewRay balance sheet include debt obligations and money owed to different ViewRay vendors, workers, and loan providers. Below is the chart of ViewRay main long-term debt accounts currently reported on its balance sheet.
You can use ViewRay financial leverage analysis tool to get a better grip on understanding its financial position

How important is ViewRay's Liquidity

ViewRay financial leverage refers to using borrowed capital as a funding source to finance ViewRay ongoing operations. It is usually used to expand the firm's asset base and generate returns on borrowed capital. ViewRay financial leverage is typically calculated by taking the company's all interest-bearing debt and dividing it by total capital. So the higher the debt-to-capital ratio (i.e., financial leverage), the riskier the company. Please check the breakdown between ViewRay's total debt and its cash.

What do experts say?

Stock analysis is a method for investors and traders to make buying and selling decisions. By studying and evaluating past and current data, investors and traders attempt to gain an edge in the markets by making informed decisions. It is good to see analyst projects for ViewRay, but it might be worth checking our own buy vs. sell analysis

Acquisition by Xie Yili Kevin of 2456 shares of ViewRay subject to Rule 16b-3

Legal trades by ViewRay insiders are very common, as founders, directors, or employees of any publicly traded firm often have stock or stock options. These trades are made public in the United States through the filing of Form 4 of the Securities and Exchange Commission. Below entry was recorded recently and is publicly available as an insider trade:
ViewRay insider trading alert for grant of common stock by Xie Yili Kevin, the corporate stakeholder, on 5th of January 2021. This event was filed by Viewray Inc with SEC on 2021-01-05. Statement of changes in beneficial ownership - SEC Form 4 [view details]   
Note, although insider trading is legal, in the United States, Canada, Australia, and Germany, for mandatory reporting purposes, corporate insiders are defined as a company's officers, directors, and any beneficial owners of more than 10% of a class of the company's equity securities.

A Deeper Perspective

The entity reported the previous year's revenue of 55.03 M. Net Loss for the year was (117.02 M) with profit before overhead, payroll, taxes, and interest of 2.42 M.

Liabilities Breakdown

10 M
Deposit Liabilities
42.1 M
Current Liabilities
23.3 M
Long-Term Liabilities
Deposit Liabilities10.02 Million
Total Liabilities96.29 Million
Current Liabilities42.09 Million
Long-Term Liabilities23.26 Million

Can ViewRay build up on the current rise?

Jensen alpha is down to 0.27. It may suggest a possible volatility slide. ViewRay shows above-average downside volatility for the selected time horizon. We advise investors to inspect ViewRay further and ensure that all market timing and asset allocation strategies are consistent with the estimation of ViewRay future alpha.

The Bottom Line

While some companies within the medical devices industry are still a little expensive, even after the recent corrections, ViewRay may offer a potential longer-term growth to investors. With an impartial outlook on the current market volatility, it may be better to hold off any inventment activity and neither take up nor drop any shares of ViewRay at this time. The ViewRay risk-reward trade off is not appealing enough to do any trading. Please use our equity advice module to run different scenarios to ensure your current risk level and investment horizon are fully reflective of your current investing preferences in regards to ViewRay.

About Contributor

This story should be regarded as informational only and should not be considered a solicitation to sell or buy any financial products. Macroaxis does not express any opinion as to the present or future value of any investments referred to in this post. This post may not be reproduced without the consent of Macroaxis LLC. Macroaxis LLC and Achuva Shats do not own shares of ViewRay. Please refer to our Terms of Use for any information regarding our disclosure principles.

Would you like to provide feedback on the content of this article?

You can get in touch with us directly or send us a quick note via email to editors@macroaxis.com